Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;15(6):314-315.
doi: 10.1038/s41582-019-0178-0.

Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome?

Anna S Berghoff  1   2 , Matthias Preusser  3   4
Affiliations

Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome?

Anna S Berghoff et al. Nat Rev Neurol. 2019 Jun.
No abstract available

PubMed Disclaimer

References

    1. Preusser, M. et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat. Rev. Neurol. 11, 504–514 (2015). - DOI
    1. Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234–239 (2019). - DOI
    1. Erhart, F. et al. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables. Acta Neuropathol. Commun. 6, 135 (2018). - DOI
    1. Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 25, 477–486 (2019). - DOI
    1. Schalper, K. A. et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat. Med. 25, 462–469 (2019). - DOI

MeSH terms

LinkOut - more resources